ClinicalTrials.gg
RecruitingNCT05883800TNT-RECORDUpdated Mar 19, 2024

Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer

An interventional study of On-couch adaptive radiotherapy in Rectal Cancer, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Haukeland University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Rectal Neoplasms with a site in Norway — 6 open to participants now, 12 under way, 3 of them phase 3. Rectal Neoplasms · Norway.

Planned enrollment
8th of 13
61 · median 106
Started
2023
the only one that year
No phase
4 of 25
1 open now
Primary completion
2026-12
later than 7 of 11 live
Registered
24th of 25
by date
Lead sponsor
1 of 25
Haukeland University Hospital

Among the 25 studies in Rectal Neoplasms with a site in Norway, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 4 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 24th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

6 of the 25 studies in Rectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Rectal Neoplasms with a site in Norway, or all of them as a file.
02

Study summary

Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).

This study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.

Read the detailed description

This is a prospective single-arm study investigating the benefit of on-couch adaptation for locally advanced rectal cancer patients prescribed with pre-operative sequential short-course radiotherapy (RT) followed by Oxaliplatin-combined chemotherapy (mFOLFOX(6) or CAPOX). On-couch adaptation, where the radiation dose is tailored to the anatomy of the patient at each radiotherapy session. Firstly, the study will investigate if on-couch adaptation result in less gastro-intestinal adverse events, secondly it will reveal if this possible reduction lead to more patients being able to fulfill all cycles of prescribed chemotherapy.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with loco-regional advanced rectal adenocarcinoma with clinical indications for short-course with TNT chemotherapy i.e. having at least one of the following T4a, CRM+ (≤1 mm), N1c, N2 or extramural vascular invasion (EMVI+). Patients presenting at least one of these criteria in addition to involvement of the pelvic sidewall lymph nodes (PSW) can optionally be considered.
  • status ≤ 1
  • Being willing and able to give full written consent for participation

Exclusion criteria

Exclusion Criteria:

  • Previous rectal cancer treatment
  • Previous irradiation to the treatment area e.g. prostate cancer
  • Hip prosthesis
  • to MRI
  • Pregnancy
  • Abnormal DPYD genotype
  • Known contraindication to 5-FU, Capecitabine or Oxaliplatin as judged by the investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intervention: daily on-couch adaptive radiotherapy

    Radiation: On-couch adaptive radiotherapy

Interventions

  • RadiationOn-couch adaptive radiotherapy

    A new treatment plan, guided by volumetric images, is created at each treatment session

    Also known as: online ART

06

What researchers measure

Primary outcomes

  1. Incidence of acute gastro-intestinal toxicity equal or higher than grade 2

    Incidence of acute gastro-intestinal toxicity from therapy graded according to CTCAE ver. 5.

    Time frame: Up to administration of the last course of chemotherapy or week 22, whichever comes first

Secondary outcomes

  1. Number of participants that require alteration of chemotherapy due to toxicity

    Alterations of chemotherapy, defined as dose-reduction or pre-maturely stopping chemotherapy administration

    Time frame: From treatment week 3 up to week 20

  2. Number of patients with disease related treatment failure

    Disease-related treatment failure include the first of any of the following events: (i) During treatment: Non-radical resection of primary tumor (R2 resection) or un-fit of for surgery due to progression, death from treatment (ii) During, or after treatment: Loco-regional recurrence (including regrowth after potential watch-and-wait), distant metastasis (including M re-staging at surgery), death from rectal cancer, second primary rectal cancer.

    Time frame: 5 years after surgery

  3. Number of patients with pathological complete response (pCR)

    pCR after completion of the intended or tolerated TNT

    Time frame: At surgery i.e. in treatment week 23-28

  4. Tumour regression grade

    Radiological based clinical response evaluation on MR (mrTRG)

    Time frame: Baseline to response evaluation on MR in up to week 25 of the study

  5. Overall survival

    Overall survival from time of inclusion until death

    Time frame: Follow-up until 5 years or death

  6. Incidence of late gastro-intestinal toxicity equal or higher than grade 2

    Incidence of late gastro-intestinal events (e.g.diarrhea, rectal hemorrhage, rectal and/or abdominal pain) from therapy graded according to CTCAE ver. 5.

    Time frame: 5 years

Other outcomes

  1. Bowel exposure

    Radiation dose to bowel

    Time frame: Treatment week 1-2

  2. Immunogenic alterations from TNT

    Presence of selected immune cells

    Time frame: Baseline and at surgery i.e. in treatment week 23-28

  3. Perfusion changes on MR

    Changes in perfusion from contrast-enhanced MR

    Time frame: Baseline and at MR response evaluation up to week 25 of the study

  4. Diffusion changes on MR

    Changes in diffusion from diffusion-weighted MR

    Time frame: Baseline and at MR response evaluation up to week 25 of the study

  5. Patient reported general outcome measures

    Quality of life using EORTC qlq-c30 questionnaire

    Time frame: Baseline and up to 5 years of the study

  6. Patient reported colo-rectal outcome measures

    Quality of life using EORTC qlq-cr29 questionnaire

    Time frame: Baseline and up to 5 years of the study

  7. Patient reported bowel-related outcome measures

    Quality of life using low anterior resection syndrome (LARS) score

    Time frame: Baseline and up to 5 years of the study

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 42 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Jun 1, 2023
StartActual
Jun 22, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05883800
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Jun 22, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Mar 19, 2024

Study contacts

Sara Pilskog, PhD
Contact
sara.margareta.cecilia.pilskog@helse-bergen.no
95890659 ext. 0047
Unn Hege Lilleøren, MD
Contact
unn.hege.lilleoren@helse-bergen.no
92054547 ext. 0047
Unn Hege Lilleøren, MD
principal investigator · Dept. of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion